The study aimed to determine short-term changes in feeding behavior following subcutaneous injections of vehicle or Cagrilintide at 3, 30, or 300 nmol/kg [2]
Lack of confirmation of actual drug intake limits the ability to draw conclusions about long-term effects on sexual health
Medication is billed separately through NovoCare
Do not combine with other GLP-1 agonists (e.g., semaglutide) or DPP-4 inhibitors

Seek medical advice if you experience: Unintentional weight changes (loss or gain of more than 5% body weight over 3-6 months without dietary or activity changes) Persistent fatigue that doesn't improve with rest and affects daily functioning Heat or cold intolerance that differs significantly from your usual tolerance Cardiac symptoms including palpitations, irregular heartbeat, or chest discomfort Tremor, anxiety, or agitation that appears without clear psychological triggers Changes in bowel habits , particularly persistent diarrhoea or constipation Menstrual irregularities or fertility concerns potentially related to metabolic dysfunction Mood changes , including depression or anxiety, especially if accompanied by physical symptoms Seek urgent same-day medical attention for: Severe palpitations or irregular heartbeat Fever with confusion or agitation (possible thyroid storm) Severe headache with palpitations and excessive sweating (possible phaeochromocytoma crisis) Sudden onset of jaundice or severe abdominal pain while taking antithyroid medication Your GP will conduct a thorough clinical assessment including medical history, physical examination, and appropriate investigations

It will be particularly insightful to study the impact of GLP-1 RAs on affective symptoms during the maintenance phase or after treatment is discontinued